These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 14657221)
1. Leishmania major LACK antigen is required for efficient vertebrate parasitization. Kelly BL; Stetson DB; Locksley RM J Exp Med; 2003 Dec; 198(11):1689-98. PubMed ID: 14657221 [TBL] [Abstract][Full Text] [Related]
2. The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156 to 173 is not required for early Th2 development in BALB/c mice. Kelly BL; Locksley RM Infect Immun; 2004 Dec; 72(12):6924-31. PubMed ID: 15557613 [TBL] [Abstract][Full Text] [Related]
3. Control of Leishmania major by a monoclonal alpha beta T cell repertoire. Reiner SL; Fowell DJ; Moskowitz NH; Swier K; Brown DR; Brown CR; Turck CW; Scott PA; Killeen N; Locksley RM J Immunol; 1998 Jan; 160(2):884-9. PubMed ID: 9551925 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087 [TBL] [Abstract][Full Text] [Related]
6. Disruption of the Putative Ribosome-Binding Motif of a Scaffold Protein Impairs Cytochrome Cardenas D; Sylvester C; Cao B; Nation CS; Pizarro JC; Lu H; Guidry J; Wojcik EJ; Kelly BL mSphere; 2019 Mar; 4(2):. PubMed ID: 30842271 [TBL] [Abstract][Full Text] [Related]
7. Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites. Courret N; Prina E; Mougneau E; Saraiva EM; Sacks DL; Glaichenhaus N; Antoine JC Eur J Immunol; 1999 Mar; 29(3):762-73. PubMed ID: 10092078 [TBL] [Abstract][Full Text] [Related]
8. T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice. Schilling S; Glaichenhaus N Infect Immun; 2001 Feb; 69(2):1212-4. PubMed ID: 11160025 [TBL] [Abstract][Full Text] [Related]
9. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC; Yang J; Zhao W; Perez LE; Cheng J Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143 [TBL] [Abstract][Full Text] [Related]
10. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana. Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565 [TBL] [Abstract][Full Text] [Related]
11. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. Prina E; Lang T; Glaichenhaus N; Antoine JC J Immunol; 1996 Jun; 156(11):4318-27. PubMed ID: 8666803 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major. Ghaffarifar F; Jorjani O; Sharifi Z; Dalimi A; Hassan ZM; Tabatabaie F; Khoshzaban F; Hezarjaribi HZ APMIS; 2013 Apr; 121(4):290-8. PubMed ID: 23030526 [TBL] [Abstract][Full Text] [Related]
13. Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice. Hezarjaribi HZ; Ghaffarifar F; Dalimi A; Sharifi Z; Jorjani O Exp Parasitol; 2013 Jul; 134(3):341-8. PubMed ID: 23541883 [TBL] [Abstract][Full Text] [Related]
14. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection. Hugentobler F; Di Roberto RB; Gillard J; Cousineau B Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408 [TBL] [Abstract][Full Text] [Related]
15. [LACK protein of Leishmania major: a pivotal antigen in the immune relation between host and parasite]. Gangneux JP Sante; 1997; 7(6):425. PubMed ID: 9503502 [No Abstract] [Full Text] [Related]
16. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection. Wakil AE; Wang ZE; Locksley RM Exp Parasitol; 1996 Nov; 84(2):214-22. PubMed ID: 8932771 [TBL] [Abstract][Full Text] [Related]
17. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice. Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Iborra S; Soto M; Carrión J; Alonso C; Requena JM Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433 [TBL] [Abstract][Full Text] [Related]
19. Amastin Knockdown in Leishmania braziliensis Affects Parasite-Macrophage Interaction and Results in Impaired Viability of Intracellular Amastigotes. de Paiva RM; Grazielle-Silva V; Cardoso MS; Nakagaki BN; Mendonça-Neto RP; Canavaci AM; Souza Melo N; Martinelli PM; Fernandes AP; daRocha WD; Teixeira SM PLoS Pathog; 2015 Dec; 11(12):e1005296. PubMed ID: 26641088 [TBL] [Abstract][Full Text] [Related]
20. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World. Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]